Printer Friendly

PHARMACOPEIA APPOINTS TWO NEW MEMBERS TO MANAGEMENT TEAM

 PRINCETON, N.J., Jan. 12 /PRNewswire/ -- Pharmacopeia, Inc. today announced it has appointed Robert A. Curtis, Pharm.D., as Vice President of Corporate Development and Business Operations and Nolan H. Sigal, M.D., Ph.D., as Vice President of Biology. Dr. Curtis has over 10 years of product and business development experience in both large pharmaceutical (Pfizer) and early-stage biotechnology companies, while Dr. Sigal has over 15 years of clinical and basic research experience in the field of immunology and cellular signal transduction, including the last 10 years at Merck and Co., Inc.
 "Pharmacopeia is truly fortunate to be able to add these two distinguished individuals to our management team," said John C. Chabala, Ph.D., President and Chief Scientific Officer of Pharmacopeia. "Dr. Curtis and Dr. Sigal both have a wealth of experience in the biopharmaceutical business, and their expertise will be a valuable asset as Pharmacopeia continues to develop its proprietary technologies for yielding enormous, chemically diverse libraries of compounds and state- of-the-art bioanalytical screening systems."
 Prior to joining Pharmacopeia, Dr. Curtis served as Vice President of Business Development at Cambridge Neuroscience, where he was responsible for strategic alliances, technology licensing, and business and market planning. Previously, he held a variety of appointments in Pfizer's International Pharmaceuticals Group, working in areas such as regulatory affairs, clinical research, and medical marketing. Dr. Curtis also served as Director of Licensing and Development for Pfizer, where he was responsible for worldwide pharmaceutical licensing and technology acquisition. Before working at Pfizer, he was Assistant Professor of Pharmacy Practice at the University of Illinois Medical Center in Chicago.
 "Pharmacopeia is really pioneering the commercialization of a new, more efficient, and more cost-effective paradigm for drug discovery," said Dr. Curtis. "I am extremely excited about joining a company whose fundamental technology for identifying small molecular weight compounds is in such demand in the pharmaceutical and biotechnology industries."
 Prior to joining Pharmacopeia, Dr. Sigal served in multiple positions at Merck, most recently as Executive Director of the Department of Immunology Research at Merck Research Laboratories, supervising a group of 40 scientists focusing on the discovery of novel therapies for autoimmune and chronic inflammatory diseases. Dr. Sigal is an internationally recognized authority in the field of lymphocyte activation and, while at Merck, his many research activities led to the discovery of several development candidates. Prior to working at Merck, Dr. Sigal served as Assistant Professor of Pediatrics at the University of Toronto.
 "I am eager to help Pharmacopeia in its quest to accelerate the rate of drug discovery and reduce its cost," said Dr. Sigal. "With the technology we have in place, and the experience of the management team we have assembled, we truly have the potential to redefine the drug discovery process."
 Pharmacopeia, based in Princeton, was formed in 1993 with a focus on novel, proprietary technology that permits the rapid synthesis, screening and optimization of large numbers of potential drugs candidates. The company's goal is to use its technology to accelerate the drug discovery process and reduce its cost. Pharmacopeia is backed by Avalon Ventures, Institutional Venture Partners, and Kleiner Perkins Caufield and Byers.
 -0- 1/12/94
 /CONTACT: John C. Chabala, Ph.D., president and chief scientific officer of Pharmacopeia, 609-987-0700, or Rich Tammero of Noonan/Russo Communications, 212-696-4455, ext. 222/


CO: Pharmacopeia, Inc. ST: New Jersey IN: MTC SU: PER

LG-MP -- NY024 -- 1336 01/12/94 10:21 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 12, 1994
Words:567
Previous Article:EMPRESAS ICA ANNOUNCES SALE OF STATE OF THE ART OFFICE COMPLEX
Next Article:PHILADELPHIA GAS WORKS $206.1 MILLION REVENUE BONDS 'A-' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters